Latest Form 144 filings
Officers, directors and other affiliates of a company file Form 144 when they place an order to sell restricted or control shares, if they plan to sell more than 5,000 shares or more than $50,000 worth within three months. It is a notice of a planned sale; officers and directors report the sale itself later on Form 4. 13D, 13G and Form 144 explained
Form 144 notices
Newest first. When a Form 144/A amends a notice, only the amendment is listed.
Filed in the last 365 days (US Eastern dates).
Form 144 filings on Livermore: Jan 4, 2023 to Nov 13, 2026.
Notices with a clearly misreported market value are left out of this list and its totals; they still appear, flagged, on the company's page. A value counts as misreported when the price per share it implies is far above the company's prices in Form 4 trades and 13F filings around the planned sale date.
- Notices
- 27
- Market value to sell
- $105.9M
- Sellers
- 14
- Companies
- 1
- Under 10b5-1 plans
- 12
| Company | Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|---|
| ASNDAscendis Pharma A/S | Sep 8, 20264:16 PM ET | Bodenhoff MadsOfficer | 3.00K | $810.6K | Sep 8, 2026 | Merrill Lynch | SEC |
| ASNDAscendis Pharma A/S | Sep 2, 202612:52 PM ET | Holtug LarsDirector | 236 | $62.3K | Sep 2, 2026 | CITIGROUP GLOBAL MARKETS | SEC |
| ASNDAscendis Pharma A/S | May 11, 20263:36 PM ET | Jensen Flemming SteenOfficer · EXECUTIVE VP HEAD OF PRODUCT SUPPLY AND QUALITY | 19.5K | $4.64M | May 11, 2026 | CITIGROUP GLOBAL MARKETS | SEC |
| ASNDAscendis Pharma A/S | Mar 9, 20265:30 PM ET | Singel StinaOfficer | 3.78K | $907.7K | Mar 9, 2026 | Merrill Lynch | SEC |
| ASNDAscendis Pharma A/S | Mar 6, 20264:21 PM ET | Bodenhoff MadsOfficer | 10.0K | $2.38M | Mar 6, 2026 | Merrill Lynch | SEC |
| ASNDAscendis Pharma A/S | Mar 6, 20268:44 AM ETAmended | Smith Scott ThomasOfficer | 10.0K | $2.40M | Mar 5, 2026 | Merrill Lynch | SEC |
| ASNDAscendis Pharma A/S | Mar 5, 20265:20 PM ET | Shu AimeeOfficer | 5.58K | $1.32M | Mar 5, 2026 | Merrill Lynch | SEC |
| ASNDAscendis Pharma A/S | Mar 5, 20265:04 PM ET | Jan Moller MikkelsenCEO · Officer | 94.0K | $22.7M | Mar 5, 2026 | J.P. Morgan Securities LLC | SEC |
| ASNDAscendis Pharma A/S | Mar 4, 20264:58 PM ET | Morrison LisaOfficer | 10.1K | $2.39M | Mar 4, 2026 | Merrill Lynch | SEC |
| ASNDAscendis Pharma A/S | Mar 4, 202610:54 AM ET | Shu AimeeOfficer · EXECUTIVE VICE PRESIDENT CHIEF MEDICAL OFFICER | 7.29K | $1.74M | Mar 4, 2026 | CITIGROUP GLOBAL MARKETS | SEC |
| ASNDAscendis Pharma A/S | Mar 2, 20265:01 PM ET | Fairey WilliamDirector | 1.80K | $435.8K | Mar 2, 202610b5-1 | CITIGROUP GLOBAL MARKETS | SEC |
| ASNDAscendis Pharma A/S | Mar 2, 20264:59 PM ET | Imani SihamDirector | 1.80K | $435.8K | Mar 2, 202610b5-1 | CITIGROUP GLOBAL MARKETS | SEC |
| ASNDAscendis Pharma A/S | Mar 2, 20264:56 PM ET | Smith Scott ThomasOfficer · EXECUTIVE VP CHIEF FINANCIAL OFFICER | 18.3K | $4.44M | Mar 2, 202610b5-1 | CITIGROUP GLOBAL MARKETS | SEC |
| ASNDAscendis Pharma A/S | Mar 2, 20264:52 PM ET | Jensen Michael WolffOfficer · EXECUTUVE VP CHIEF LEGAL OFFICER | 18.3K | $4.44M | Mar 2, 202610b5-1 | CITIGROUP GLOBAL MARKETS | SEC |
| ASNDAscendis Pharma A/S | Mar 2, 20264:44 PM ET | Bodenhoff MadsOfficer · SENIOR VP PRINCIPAL ACCOUNTING OFFICER | 6.87K | $1.66M | Mar 2, 202610b5-1 | CITIGROUP GLOBAL MARKETS | SEC |
| ASNDAscendis Pharma A/S | Mar 2, 20264:40 PM ET | Pedersen Anni Lotte Kirstine SonderbjergOfficer · EXECUTIVE VP CHIEF ADMINISTRATIVE OFFICER | 10.8K | $2.61M | Mar 2, 202610b5-1 | CITIGROUP GLOBAL MARKETS | SEC |
| ASNDAscendis Pharma A/S | Mar 2, 20264:35 PM ET | Morrison LisaDirector | 2.10K | $508.4K | Mar 2, 202610b5-1 | CITIGROUP GLOBAL MARKETS | SEC |
| ASNDAscendis Pharma A/S | Mar 2, 20264:32 PM ET | Holtug LarsDirector | 2.10K | $508.4K | Mar 2, 202610b5-1 | CITIGROUP GLOBAL MARKETS | SEC |
| ASNDAscendis Pharma A/S | Mar 2, 20264:27 PM ET | Sprogoe KennettOfficer · EXECUTIVE VP HEAD OF RESEARCH AND PROD DEVELOPMENT | 10.8K | $2.61M | Mar 2, 202610b5-1 | CITIGROUP GLOBAL MARKETS | SEC |
| ASNDAscendis Pharma A/S | Mar 2, 20264:23 PM ET | Jensen Flemming SteenOfficer · EXECUTIVE VP HEAD OF PRODUCT SUPPLY AND QUALITY | 10.8K | $2.61M | Mar 2, 202610b5-1 | CITIGROUP GLOBAL MARKETS | SEC |
| ASNDAscendis Pharma A/S | Mar 2, 20264:18 PM ET | Cha AlbertDirector | 2.10K | $508.4K | Mar 2, 202610b5-1 | CITIGROUP GLOBAL MARKETS | SEC |
| ASNDAscendis Pharma A/S | Jan 13, 20262:01 PM ET | Mikkelsen Jan MollerOfficer · PRESIDENT CEO | 86.9K | $18.4M | Jan 13, 202610b5-1 | CITIGROUP GLOBAL MARKETS | SEC |
| ASNDAscendis Pharma A/S | Dec 4, 20255:07 PM ET | Jensen Michael WolffOfficer | 10.0K | $2.08M | Dec 4, 2025 | Merrill Lynch | SEC |
| ASNDAscendis Pharma A/S | Dec 2, 20255:04 PM ET | Jan Moller MikkelsenCEO · Officer | 100.0K | $21.1M | Dec 2, 2025 | J.P. Morgan Securities LLC | SEC |
| ASNDAscendis Pharma A/S | Dec 2, 20254:54 PM ET | Sprogoe KennettOfficer | 10.0K | $2.09M | Dec 2, 2025 | Merrill Lynch | SEC |
| ASNDAscendis Pharma A/S | Dec 2, 20254:43 PM ET | Jensen Flemming SteenOfficer | 10.0K | $2.06M | Dec 2, 2025 | Merrill Lynch | SEC |
| ASNDAscendis Pharma A/S | Dec 1, 20252:30 PM ET | Singel StinaOfficer | 218 | $45.7K | Dec 1, 2025 | Merrill Lynch | SEC |